Anchor Investment Management LLC Grows Position in Novo Nordisk A/S (NYSE:NVO)

Anchor Investment Management LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,447 shares of the company’s stock after buying an additional 297 shares during the quarter. Anchor Investment Management LLC’s holdings in Novo Nordisk A/S were worth $1,601,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of NVO. 1620 Investment Advisors Inc. purchased a new stake in Novo Nordisk A/S during the 2nd quarter valued at $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S in the second quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC grew its stake in Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the last quarter. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at about $28,000. Finally, Abound Wealth Management raised its holdings in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on NVO shares. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $150.40.

Novo Nordisk A/S Stock Down 2.7 %

Novo Nordisk A/S stock opened at $108.63 on Friday. Novo Nordisk A/S has a 12 month low of $96.53 and a 12 month high of $148.15. The stock has a market capitalization of $487.48 billion, a PE ratio of 35.16, a price-to-earnings-growth ratio of 1.43 and a beta of 0.40. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The business has a 50 day simple moving average of $110.88 and a 200-day simple moving average of $126.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.